Calcium cycling proteins and their association with heart failure

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 4, 2011, Pages 620-624

  Hadri, L ^a   Hajjar, R J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; CALCIUM; CYCLIC AMP DEPENDENT PROTEIN KINASE; MESSENGER RNA; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PLACEBO; PLB PROTEIN; RYANODINE RECEPTOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SERCA2A PROTEIN; SERINE ARGININE RICH PROTEIN; TROPONIN C; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM HOMEOSTASIS; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CONGESTIVE HEART FAILURE; DISEASE MODEL; EXCITATION CONTRACTION COUPLING; HEART CONTRACTION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; KNOCKOUT MOUSE; NONHUMAN; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SARCOPLASMIC RETICULUM;

ANIMALS; CALCIUM; CALCIUM-BINDING PROTEINS; EXCITATION CONTRACTION COUPLING; HEART FAILURE; HOMEOSTASIS; HUMANS; MYOCYTES, CARDIAC;

EID: 80052963462     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.161     Document Type: Article

References (40)

1. Lloyd-Jones, D. et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119, 480-486 (2009).
2. Bers, D.M. Calcium cycling and signaling in cardiac myocytes. Annu. Rev. Physiol. 70, 23-49 (2008). (Pubitemid 351738170)
3. Brodde, O.E., Bruck, H. & Leineweber, K. Cardiac adrenoceptors: physiological and pathophysiological relevance. J. Pharmacol. Sci. 100, 323-337 (2006). (Pubitemid 44609527)
4. Ahmet, I., Krawczyk, M., Heller, P., Moon, C., Lakatta, E.G. & Talan, M.I. Beneficial effects of chronic pharmacological manipulation of beta-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation 110, 1083-1090 (2004). (Pubitemid 39319006)
5. Lipskaia, L., Chemaly, E.R., Hadri, L., Lompre, A.M. & Hajjar, R.J. Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure. Expert Opin. Biol. Ther. 10, 29-41 (2010).
6. Lompr A.M., Hajjar, R.J., Harding, S.E., Kranias, E.G., Lohse, M.J. & Marks, A.R. Ca2+ cycling and new therapeutic approaches for heart failure. Circulation 121, 822-830 (2010).
7. Engelhardt, S., Hein, L., Wiesmann, F. & Lohse, M.J. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc. Natl. Acad. Sci. USA 96, 7059-7064 (1999). (Pubitemid 29275009)
8. Bisognano, J.D. et al. Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J. Mol. Cell. Cardiol. 32, 817-830 (2000).
9. Liggett, S.B. et al. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 101, 1707-1714 (2000). (Pubitemid 30196632)
10. T evaearai, H.T., Eckhart, A.D., Walton, G.B., Keys, J.R., Wilson, K. & Koch, W.J. Myocardial gene transfer and overexpression of beta2-adrenergic receptors potentiates the functional recovery of unloaded failing hearts. Circulation 106, 124-129 (2002). (Pubitemid 34747452)
11. C ommunal, C. & Colucci, W.S. The control of cardiomyocyte apoptosis via the beta-adrenergic signaling pathways. Arch. Mal. Coeur Vaiss. 98, 236-241 (2005).
12. Marx, S.O. et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101, 365-376 (2000).
13. Wehrens, X.H., Lehnart, S.E., Reiken, S., Vest, J.A., Wronska, A. & Marks, A.R. Ryanodine receptor/calcium release channel PKA phosphorylation: a critical mediator of heart failure progression. Proc. Natl. Acad. Sci. USA 103, 511-518 (2006). (Pubitemid 43153055)
14. Shan, J. et al. Role of chronic ryanodine receptor phosphorylation in heart failure and ?-adrenergic receptor blockade in mice. J. Clin. Invest. 120, 4375-4387 (2010).
15. Lehnart, S.E. et al. Phosphodiesterase 4D deficiency in the ryanodinereceptor complex promotes heart failure and arrhythmias. Cell 123, 25-35 (2005). (Pubitemid 41414526)
16. Ling, H. et al. Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J. Clin. Invest. 119, 1230-1240 (2009).
17. Kawase, Y., Ladage, D. & Hajjar, R.J. Rescuing the failing heart by targeted gene transfer. J. Am. Coll. Cardiol. 57, 1169-1180 (2011).
18. Baker, D.L. et al. Targeted overexpression of the sarcoplasmic reticulum Ca2+-ATPase increases cardiac contractility in transgenic mouse hearts. Circ. Res. 83, 1205-1214 (1998). (Pubitemid 29006035)
19. Giordano, F.J., He, H., McDonough, P., Meyer, M., Sayen, M.R. & Dillmann, W.H. Adenovirus-mediated gene transfer reconstitutes depressed sarcoplasmic reticulum Ca2+-ATPase levels and shortens prolonged cardiac myocyte Ca2+ transients. Circulation 96, 400-403 (1997). (Pubitemid 27329410)
20. Hajjar, R.J., Kang, J.X., Gwathmey, J.K. & Rosenzweig, A. Physiological effects of adenoviral gene transfer of sarcoplasmic reticulum calcium ATPase in isolated rat myocytes. Circulation 95, 423-429 (1997). (Pubitemid 27056210)
21. Miyamoto, M.I. et al. Adenoviral gene transfer of SERCA2a improves leftventricular function in aortic-banded rats in transition to heart failure. Proc. Natl. Acad. Sci. USA 97, 793-798 (2000). (Pubitemid 30070389)
22. del Monte, F. et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation 104, 1424-1429 (2001). (Pubitemid 32880157)
23. Sakata, S. et al. Transcoronary gene transfer of SERCA2a increases coronary blood flow and decreases cardiomyocyte size in a type 2 diabetic rat model. Am. J. Physiol. Heart Circ. Physiol. 292, H1204-H1207 (2007).
24. Kawase, Y. et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J. Am. Coll. Cardiol. 51, 1112-1119 (2008). (Pubitemid 351374774)
25. Hadri, L. et al. SERCA2a gene transfer enhances eNOS expression and activity in endothelial cells. Mol. Ther. 18, 1284-1292 (2010).
26. Beeri, R. et al. Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation. Circ. Heart Fail. 3, 627-634 (2010).
27. Hajjar, R.J. et al. Design of a phase ? trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J. Card. Fail. 14, 355-367 (2008). (Pubitemid 351756538)
28. Jaski, B.E. et al.; Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) Trial Investigators. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase ? clinical trial. J. Card. Fail. 15, 171-181 (2009).
29. C haanine, A.H., Kalman, J. & Hajjar, R.J. Cardiac gene therapy. Semin. Thorac. Cardiovasc. Surg. 22, 127-139 (2010).
30. Suckau, L. et al. Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 119, 1241-1252 (2009).
31. Minamisawa, S. et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99, 313-322 (1999). (Pubitemid 29519910)
32. Zhang, T. et al. Phospholamban ablation rescues sarcoplasmic reticulum Ca(2+) handling but exacerbates cardiac dysfunction in CaMKIIdelta(C) transgenic mice. Circ. Res. 106, 354-362 (2010).
33. Haghighi, K. et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc. Natl. Acad. Sci. USA 103, 1388-1393 (2006). (Pubitemid 43191175)
34. Nicolaou, P., Hajjar, R.J. & Kranias, E.G. Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology. J. Mol. Cell. Cardiol. 47, 365-371 (2009).
35. El-Armouche, A., Pamminger, T., Ditz, D., Zolk, O. & Eschenhagen, T. Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc. Res. 61, 87-93 (2004). (Pubitemid 38056684)
36. C arr, A.N. et al. Type 1 phosphatase, a negative regulator of cardiac function. Mol. Cell. Biol. 22, 4124-4135 (2002). (Pubitemid 34556583)
37. Pathak, A. et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ. Res. 96, 756-766 (2005). (Pubitemid 40559515)
38. El-Armouche, A. et al. Evidence for protein phosphatase inhibitor-1 playing an amplifier role in beta-adrenergic signaling in cardiac myocytes. FASEB J. 17, 437-439 (2003).
39. Nicolaou, P. et al. Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury. Circ. Res. 104, 1012-1020 (2009).
40. Wittkper, K. et al. Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. J. Clin. Invest. 120, 617-626 (2010).